Global Hyperphosphatemia Drugs

Hyperphosphatemia Drugs Comprehensive Study by Type (Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder), Application (Hospitals, Clinics, Others), Form (Tablets, Syrups, Capsules), Distribution Channel (Hospital Pharma, Specialty Pharma Retail Stores) Players and Region - Global Market Outlook to 2030

Hyperphosphatemia Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hyperphosphatemia Drugs
In dialysis patients, hyperphosphatemia is thought to be an independent risk factor for cardiovascular morbidity and mortality. Phosphate binders are widely prescribed in patients with progressive renal disease when phosphate management with diet or dialysis is ineffective. In uremic patients, cardiovascular mortality is the main cause of death. Appropriate phosphate lowering is thought to be essential for CKD patients' health and longevity. Phosphate binders are the most effective treatment choice in this case, though dietary phosphate restriction and increased dialysis are helpful adjuncts. Sevelamer hydrochloride and lanthanum carbonate, two new non-aluminum and non-calcium phosphate binders, were recently introduced. Aside from its phosphate-lowering effect, sevelamer has been linked to a reduction in coronary and aortic calcification, as well as other pleiotropic effects, especially on lipid metabolism.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hyperphosphatemia Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), AMAG Pharmaceuticals (United States), Johnson & Johnson (United States), Keryx Biopharmaceuticals (Akebia Therapeutics Inc.) (United States), DSM Biotech Pharmacal N.V. (United States), Sun Pharm Inc (India), Zeria Pharmaceutical (Japan), Bruno Pharmaceutical SpA (Italy) and Fermenta Biotech Ltd (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Ultragenyx Pharmaceutical (United States), Cipla (India), Ardelyx, Inc. (United States) and Shire plc (United States).

Segmentation Overview
AMA Research has segmented the market of Global Hyperphosphatemia Drugs market by Type (Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder and Calcium Phosphate Binder), Application (Hospitals, Clinics and Others) and Region.



On the basis of geography, the market of Hyperphosphatemia Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Tablets will boost the Hyperphosphatemia Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharma will boost the Hyperphosphatemia Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technical Progress in Medical Industry

Market Growth Drivers:
Prevalence of Cardiovascular Disorders and Rising Geriatric Population

Challenges:
Regulatory Approval

Restraints:
Side Effects and Adverse Reactions

Opportunities:
Unexplored Markets and Heavy Investments in Healthcare Research & Development

Market Leaders and their expansionary development strategies

On 15th September, 2020 - Ardelyx Announced FDA Acceptance for its New Drug Application (NDA) of “Tenapanor” for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis. The Approval Is Supported by Three Successful Phase 3 Trials Involving Over 1,000 Patients That Evaluated the Use of Tenapanor.
United States, FDA CFR - Code of Federal Regulations Title 21 “PART 310, Subpart E” - USDA is the key Regulatory Authority Responsible for Approval, Inspection, Classification and Dosage Limitations of Hyperphosphatemia Drugs across the United States. Any New Entrant is Required to have a Regulatory Clearance form FDA.

Key Target Audience
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Aluminum Phosphate Binder
  • Iron Phosphate Binder
  • Magnesium Phosphate Binder
  • Calcium Phosphate Binder
By Application
  • Hospitals
  • Clinics
  • Others
By Form
  • Tablets
  • Syrups
  • Capsules

By Distribution Channel
  • Hospital Pharma
  • Specialty Pharma Retail Stores

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Cardiovascular Disorders
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Regulatory Approval
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hyperphosphatemia Drugs, by Type, Application, Form, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hyperphosphatemia Drugs (Value)
      • 5.2.1. Global Hyperphosphatemia Drugs by: Type (Value)
        • 5.2.1.1. Aluminum Phosphate Binder
        • 5.2.1.2. Iron Phosphate Binder
        • 5.2.1.3. Magnesium Phosphate Binder
        • 5.2.1.4. Calcium Phosphate Binder
      • 5.2.2. Global Hyperphosphatemia Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Hyperphosphatemia Drugs by: Form (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. Syrups
        • 5.2.3.3. Capsules
      • 5.2.4. Global Hyperphosphatemia Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharma
        • 5.2.4.2. Specialty Pharma Retail Stores
      • 5.2.5. Global Hyperphosphatemia Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hyperphosphatemia Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AMAG Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Keryx Biopharmaceuticals (Akebia Therapeutics Inc.) (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DSM Biotech Pharmacal N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sun Pharm Inc (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Zeria Pharmaceutical (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bruno Pharmaceutical SpA (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Fermenta Biotech Ltd (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hyperphosphatemia Drugs Sale, by Type, Application, Form, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hyperphosphatemia Drugs (Value)
      • 7.2.1. Global Hyperphosphatemia Drugs by: Type (Value)
        • 7.2.1.1. Aluminum Phosphate Binder
        • 7.2.1.2. Iron Phosphate Binder
        • 7.2.1.3. Magnesium Phosphate Binder
        • 7.2.1.4. Calcium Phosphate Binder
      • 7.2.2. Global Hyperphosphatemia Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Hyperphosphatemia Drugs by: Form (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. Syrups
        • 7.2.3.3. Capsules
      • 7.2.4. Global Hyperphosphatemia Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharma
        • 7.2.4.2. Specialty Pharma Retail Stores
      • 7.2.5. Global Hyperphosphatemia Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hyperphosphatemia Drugs: by Type(USD Million)
  • Table 2. Hyperphosphatemia Drugs Aluminum Phosphate Binder , by Region USD Million (2018-2023)
  • Table 3. Hyperphosphatemia Drugs Iron Phosphate Binder , by Region USD Million (2018-2023)
  • Table 4. Hyperphosphatemia Drugs Magnesium Phosphate Binder , by Region USD Million (2018-2023)
  • Table 5. Hyperphosphatemia Drugs Calcium Phosphate Binder , by Region USD Million (2018-2023)
  • Table 6. Hyperphosphatemia Drugs: by Application(USD Million)
  • Table 7. Hyperphosphatemia Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 8. Hyperphosphatemia Drugs Clinics , by Region USD Million (2018-2023)
  • Table 9. Hyperphosphatemia Drugs Others , by Region USD Million (2018-2023)
  • Table 10. Hyperphosphatemia Drugs: by Form(USD Million)
  • Table 11. Hyperphosphatemia Drugs Tablets , by Region USD Million (2018-2023)
  • Table 12. Hyperphosphatemia Drugs Syrups , by Region USD Million (2018-2023)
  • Table 13. Hyperphosphatemia Drugs Capsules , by Region USD Million (2018-2023)
  • Table 14. Hyperphosphatemia Drugs: by Distribution Channel(USD Million)
  • Table 15. Hyperphosphatemia Drugs Hospital Pharma , by Region USD Million (2018-2023)
  • Table 16. Hyperphosphatemia Drugs Specialty Pharma Retail Stores , by Region USD Million (2018-2023)
  • Table 17. South America Hyperphosphatemia Drugs, by Country USD Million (2018-2023)
  • Table 18. South America Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 19. South America Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 20. South America Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 21. South America Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 22. Brazil Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 23. Brazil Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 24. Brazil Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 25. Brazil Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 26. Argentina Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 27. Argentina Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 28. Argentina Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 29. Argentina Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 30. Rest of South America Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 33. Rest of South America Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 34. Asia Pacific Hyperphosphatemia Drugs, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 38. Asia Pacific Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 39. China Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 40. China Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 41. China Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 42. China Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 43. Japan Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 44. Japan Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 45. Japan Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 46. Japan Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 47. India Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 48. India Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 49. India Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 50. India Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 51. South Korea Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 52. South Korea Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 53. South Korea Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 54. South Korea Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 55. Taiwan Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 56. Taiwan Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 57. Taiwan Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 58. Taiwan Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 59. Australia Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 60. Australia Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 61. Australia Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 62. Australia Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 67. Europe Hyperphosphatemia Drugs, by Country USD Million (2018-2023)
  • Table 68. Europe Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 69. Europe Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 70. Europe Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 71. Europe Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 72. Germany Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 73. Germany Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 74. Germany Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 75. Germany Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 76. France Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 77. France Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 78. France Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 79. France Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 80. Italy Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 81. Italy Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 82. Italy Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 83. Italy Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 84. United Kingdom Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 87. United Kingdom Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 88. Netherlands Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 89. Netherlands Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 90. Netherlands Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 91. Netherlands Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 92. Rest of Europe Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 95. Rest of Europe Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 96. MEA Hyperphosphatemia Drugs, by Country USD Million (2018-2023)
  • Table 97. MEA Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 98. MEA Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 99. MEA Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 100. MEA Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 101. Middle East Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 102. Middle East Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 103. Middle East Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 104. Middle East Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 105. Africa Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 106. Africa Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 107. Africa Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 108. Africa Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 109. North America Hyperphosphatemia Drugs, by Country USD Million (2018-2023)
  • Table 110. North America Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 111. North America Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 112. North America Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 113. North America Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 114. United States Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 115. United States Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 116. United States Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 117. United States Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 118. Canada Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 119. Canada Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 120. Canada Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 121. Canada Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 122. Mexico Hyperphosphatemia Drugs, by Type USD Million (2018-2023)
  • Table 123. Mexico Hyperphosphatemia Drugs, by Application USD Million (2018-2023)
  • Table 124. Mexico Hyperphosphatemia Drugs, by Form USD Million (2018-2023)
  • Table 125. Mexico Hyperphosphatemia Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Hyperphosphatemia Drugs: by Type(USD Million)
  • Table 137. Hyperphosphatemia Drugs Aluminum Phosphate Binder , by Region USD Million (2025-2030)
  • Table 138. Hyperphosphatemia Drugs Iron Phosphate Binder , by Region USD Million (2025-2030)
  • Table 139. Hyperphosphatemia Drugs Magnesium Phosphate Binder , by Region USD Million (2025-2030)
  • Table 140. Hyperphosphatemia Drugs Calcium Phosphate Binder , by Region USD Million (2025-2030)
  • Table 141. Hyperphosphatemia Drugs: by Application(USD Million)
  • Table 142. Hyperphosphatemia Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 143. Hyperphosphatemia Drugs Clinics , by Region USD Million (2025-2030)
  • Table 144. Hyperphosphatemia Drugs Others , by Region USD Million (2025-2030)
  • Table 145. Hyperphosphatemia Drugs: by Form(USD Million)
  • Table 146. Hyperphosphatemia Drugs Tablets , by Region USD Million (2025-2030)
  • Table 147. Hyperphosphatemia Drugs Syrups , by Region USD Million (2025-2030)
  • Table 148. Hyperphosphatemia Drugs Capsules , by Region USD Million (2025-2030)
  • Table 149. Hyperphosphatemia Drugs: by Distribution Channel(USD Million)
  • Table 150. Hyperphosphatemia Drugs Hospital Pharma , by Region USD Million (2025-2030)
  • Table 151. Hyperphosphatemia Drugs Specialty Pharma Retail Stores , by Region USD Million (2025-2030)
  • Table 152. South America Hyperphosphatemia Drugs, by Country USD Million (2025-2030)
  • Table 153. South America Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 154. South America Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 155. South America Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 156. South America Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 157. Brazil Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 158. Brazil Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 159. Brazil Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 160. Brazil Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 161. Argentina Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 162. Argentina Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 163. Argentina Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 164. Argentina Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 165. Rest of South America Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 166. Rest of South America Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 167. Rest of South America Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 168. Rest of South America Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 169. Asia Pacific Hyperphosphatemia Drugs, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 171. Asia Pacific Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 172. Asia Pacific Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 173. Asia Pacific Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 174. China Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 175. China Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 176. China Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 177. China Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 178. Japan Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 179. Japan Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 180. Japan Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 181. Japan Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 182. India Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 183. India Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 184. India Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 185. India Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 186. South Korea Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 187. South Korea Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 188. South Korea Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 189. South Korea Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 190. Taiwan Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 191. Taiwan Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 192. Taiwan Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 193. Taiwan Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 194. Australia Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 195. Australia Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 196. Australia Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 197. Australia Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 202. Europe Hyperphosphatemia Drugs, by Country USD Million (2025-2030)
  • Table 203. Europe Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 204. Europe Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 205. Europe Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 206. Europe Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 207. Germany Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 208. Germany Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 209. Germany Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 210. Germany Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 211. France Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 212. France Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 213. France Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 214. France Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 215. Italy Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 216. Italy Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 217. Italy Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 218. Italy Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 219. United Kingdom Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 220. United Kingdom Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 221. United Kingdom Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 222. United Kingdom Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 223. Netherlands Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 224. Netherlands Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 225. Netherlands Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 226. Netherlands Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 227. Rest of Europe Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 228. Rest of Europe Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 229. Rest of Europe Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 230. Rest of Europe Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 231. MEA Hyperphosphatemia Drugs, by Country USD Million (2025-2030)
  • Table 232. MEA Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 233. MEA Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 234. MEA Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 235. MEA Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 236. Middle East Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 237. Middle East Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 238. Middle East Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 239. Middle East Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 240. Africa Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 241. Africa Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 242. Africa Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 243. Africa Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 244. North America Hyperphosphatemia Drugs, by Country USD Million (2025-2030)
  • Table 245. North America Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 246. North America Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 247. North America Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 248. North America Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 249. United States Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 250. United States Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 251. United States Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 252. United States Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 253. Canada Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 254. Canada Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 255. Canada Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 256. Canada Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 257. Mexico Hyperphosphatemia Drugs, by Type USD Million (2025-2030)
  • Table 258. Mexico Hyperphosphatemia Drugs, by Application USD Million (2025-2030)
  • Table 259. Mexico Hyperphosphatemia Drugs, by Form USD Million (2025-2030)
  • Table 260. Mexico Hyperphosphatemia Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hyperphosphatemia Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Hyperphosphatemia Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Hyperphosphatemia Drugs: by Form USD Million (2018-2023)
  • Figure 7. Global Hyperphosphatemia Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Hyperphosphatemia Drugs Share (%), by Country
  • Figure 9. Asia Pacific Hyperphosphatemia Drugs Share (%), by Country
  • Figure 10. Europe Hyperphosphatemia Drugs Share (%), by Country
  • Figure 11. MEA Hyperphosphatemia Drugs Share (%), by Country
  • Figure 12. North America Hyperphosphatemia Drugs Share (%), by Country
  • Figure 13. Global Hyperphosphatemia Drugs share by Players 2023 (%)
  • Figure 14. Global Hyperphosphatemia Drugs share by Players (Top 3) 2023(%)
  • Figure 15. Global Hyperphosphatemia Drugs share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 21. AMAG Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 22. AMAG Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 23. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 25. Keryx Biopharmaceuticals (Akebia Therapeutics Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 26. Keryx Biopharmaceuticals (Akebia Therapeutics Inc.) (United States) Revenue: by Geography 2023
  • Figure 27. DSM Biotech Pharmacal N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 28. DSM Biotech Pharmacal N.V. (United States) Revenue: by Geography 2023
  • Figure 29. Sun Pharm Inc (India) Revenue, Net Income and Gross profit
  • Figure 30. Sun Pharm Inc (India) Revenue: by Geography 2023
  • Figure 31. Zeria Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Zeria Pharmaceutical (Japan) Revenue: by Geography 2023
  • Figure 33. Bruno Pharmaceutical SpA (Italy) Revenue, Net Income and Gross profit
  • Figure 34. Bruno Pharmaceutical SpA (Italy) Revenue: by Geography 2023
  • Figure 35. Fermenta Biotech Ltd (India) Revenue, Net Income and Gross profit
  • Figure 36. Fermenta Biotech Ltd (India) Revenue: by Geography 2023
  • Figure 37. Global Hyperphosphatemia Drugs: by Type USD Million (2025-2030)
  • Figure 38. Global Hyperphosphatemia Drugs: by Application USD Million (2025-2030)
  • Figure 39. Global Hyperphosphatemia Drugs: by Form USD Million (2025-2030)
  • Figure 40. Global Hyperphosphatemia Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 41. South America Hyperphosphatemia Drugs Share (%), by Country
  • Figure 42. Asia Pacific Hyperphosphatemia Drugs Share (%), by Country
  • Figure 43. Europe Hyperphosphatemia Drugs Share (%), by Country
  • Figure 44. MEA Hyperphosphatemia Drugs Share (%), by Country
  • Figure 45. North America Hyperphosphatemia Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • AMAG Pharmaceuticals (United States)
  • Johnson & Johnson (United States)
  • Keryx Biopharmaceuticals (Akebia Therapeutics Inc.) (United States)
  • DSM Biotech Pharmacal N.V. (United States)
  • Sun Pharm Inc (India)
  • Zeria Pharmaceutical (Japan)
  • Bruno Pharmaceutical SpA (Italy)
  • Fermenta Biotech Ltd (India)
Additional players considered in the study are as follows:
Ultragenyx Pharmaceutical (United States) , Cipla (India) , Ardelyx, Inc. (United States) , Shire plc (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 214 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hyperphosphatemia Drugs Quantitative research analysis
Global Hyperphosphatemia Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), AMAG Pharmaceuticals (United States), Johnson & Johnson (United States), Keryx Biopharmaceuticals (Akebia Therapeutics Inc.) (United States), DSM Biotech Pharmacal N.V. (United States), Sun Pharm Inc (India), Zeria Pharmaceutical (Japan), Bruno Pharmaceutical SpA (Italy) and Fermenta Biotech Ltd (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technical Progress in Medical Industry" is seen as one of major influencing trends for Hyperphosphatemia Drugs Market during projected period 2023-2030.
The Hyperphosphatemia Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hyperphosphatemia Drugs Report?

Have a Query? Click Here

Other Related Reports

Cancer CDK Inhibitors Comprehensive Study by Type (Ibrance (palbociclib), Kisqali (ribociclib), Verzenio (abemaciclib)), Application (Hospitals, Clinics, Other), Distribution Channel (Hospital Pharma...
$ 3350
Human Chorionic Gonadotropin Comprehensive Study by Technology (Natural Source Extraction, Recombinant Technology), End User (Fertility Clinics, Research Institutions, Others), Therapeutic Area (Fema...
$ 3450
Hib Vaccine Comprehensive Study by Type (Type 1-HIB Vaccine, Type 2- DTaP-IPV), Form (Liquid Monovalent HIB, Liquid Combination HIB, Lyophilized Monovalent HIB, Lyophilized Combination HIB), Age Grou...
$ 3750
Breast Cancer Predictive Genetic Testing Comprehensive Study by Type (High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes), Application (Hospitals, Clinic Center, Pharmaceuticals,...
$ 3500
Adenovirus Vaccine Comprehensive Study by Type (Type 4 Vaccine, Type 7 Vaccine), Application (Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - ...
$ 3500
Allergic Rhinitis Drugs Comprehensive Study by Type (Corticosteroids, Antihistamines, Vasoconstrictors, Pratropium Bromide, Others (Leukotrienes, Cromoglycate)), Application (Non-Allergic Rhinitis, M...
$ 3650